NasdaqGS:ENDP

Stock Analysis Report

Executive Summary

Endo International plc manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally.

Snowflake

Fundamentals

Mediocre balance sheet with moderate growth potential.

Risks

  • Endo International has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has Endo International's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

36.8%

NasdaqGS:ENDP

0.7%

US Pharmaceuticals

1.1%

US Market


1 Year Return

-73.5%

NasdaqGS:ENDP

-8.5%

US Pharmaceuticals

2.1%

US Market

ENDP underperformed the Pharmaceuticals industry which returned -7.3% over the past year.

ENDP underperformed the Market in United States of America which returned 2% over the past year.


Share holder returns

ENDPIndustryMarket
7 Day36.8%0.7%1.1%
30 Day85.8%0.7%3.7%
90 Day6.1%-4.8%2.3%
1 Year-73.5%-73.5%-6.2%-8.5%4.4%2.1%
3 Year-79.1%-79.1%12.3%4.5%47.0%37.4%
5 Year-93.7%-93.7%21.0%8.0%61.6%43.8%

Price Volatility Vs. Market

How volatile is Endo International's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Endo International undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Endo International's share price is below the future cash flow value, and at a moderate discount (> 20%).

Endo International's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Endo International is loss making, we can't compare its value to the US Pharmaceuticals industry average.

Endo International is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Endo International, we can't assess if its growth is good value.


Price Based on Value of Assets

Endo International has negative assets, we can't compare the value of its assets to the US Pharmaceuticals industry average.


Next Steps

Future Growth

How is Endo International expected to perform in the next 1 to 3 years based on estimates from 13 analysts?

35.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Endo International's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.

Endo International's earnings are expected to grow significantly at over 20% yearly.

Endo International's revenues are expected to decrease over the next 1-3 years, this is below the United States of America market average.

Endo International's earnings growth is expected to exceed the United States of America market average.

Endo International's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Endo International will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Endo International performed over the past 5 years?

-22.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Endo International does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Endo International's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Endo International's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Endo International has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

Endo International used its assets less efficiently than the US Pharmaceuticals industry average last year based on Return on Assets.


Return on Capital Employed

It is difficult to establish if Endo International improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Endo International's financial position?


Financial Position Analysis

Endo International is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Endo International's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Endo International has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if Endo International's debt level has increased considering it has negative shareholder equity.


Balance Sheet

Low level of unsold assets.

Endo International has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Whilst loss making Endo International has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.

Whilst loss making Endo International has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 46.6% per year.


Next Steps

Dividend

What is Endo International's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Endo International's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Endo International's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Endo International has not reported any payouts.

Unable to verify if Endo International's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Endo International has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Endo International's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Endo International's salary, the management and board of directors tenure and is there insider trading?

2.8yrs

Average management tenure


CEO

Paul Campanelli (57yo)

3yrs

Tenure

US$19,970,703

Compensation

Mr. Paul V. Campanelli has been the Chief Executive Officer, President, and Executive Director at Endo International plc since September 23, 2016. Mr. Campanelli joined Endo in 2015 as the President of Par ...


CEO Compensation Analysis

Paul's remuneration is higher than average for companies of similar size in United States of America.

Paul's compensation has increased whilst company is loss making.


Management Age and Tenure

2.8yrs

Average Tenure

47yo

Average Age

The tenure for the Endo International management team is about average.


Board Age and Tenure

5.6yrs

Average Tenure

70yo

Average Age

The tenure for the Endo International board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellUS$114,10010 Dec 18
William Montague
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares10,000
Max PriceUS$11.41

Ownership Breakdown


Management Team

  • Terry Coughlin (53yo)

    Executive VP & COO

    • Tenure: 2.8yrs
    • Compensation: US$3.13m
  • Matt Maletta (47yo)

    Executive VP & Chief Legal Officer

    • Tenure: 4.3yrs
    • Compensation: US$2.55m
  • Paul Campanelli (57yo)

    President

    • Tenure: 3yrs
    • Compensation: US$19.97m
  • Laure Park

    Senior Vice President of Investor Relations & Corporate Affairs

    • Tenure: 1.1yrs
  • Blaise Coleman (45yo)

    Executive VP & CFO

    • Tenure: 2.8yrs
    • Compensation: US$2.64m
  • Joseph Barbarite

    Executive Vice President of Global Quality and Compliance

    • Tenure: 2.8yrs
  • Mark Bradley

    Senior VP of Corporate Development & Treasurer

    • Tenure: 2.8yrs
  • Carrie Nichol (39yo)

    Senior VP

    • Tenure: 1.4yrs
  • Susan Williamson

    Senior VP & Chief Compliance Officer

    • Tenure: 1.4yrs
  • Tracy Basso

    Chief Human Resources Officer

    • Tenure: 0.7yrs

Board Members

  • Michael Hyatt (73yo)

    Independent Director

    • Tenure: 5.6yrs
    • Compensation: US$315.00k
  • Roger Kimmel (73yo)

    Chairman of the Board

    • Tenure: 5.6yrs
    • Compensation: US$450.00k
  • Bill Montague (72yo)

    Independent Director

    • Tenure: 5.6yrs
    • Compensation: US$320.00k
  • Shane Cooke (57yo)

    Independent Director

    • Tenure: 5.2yrs
    • Compensation: US$325.00k
  • Sharad Mansukani (49yo)

    Senior Independent Director

    • Tenure: 1.4yrs
    • Compensation: US$360.00k
  • Nancy Hutson (70yo)

    Independent Director

    • Tenure: 5.6yrs
    • Compensation: US$320.00k
  • Paul Campanelli (57yo)

    President

    • Tenure: 3yrs
    • Compensation: US$19.97m

Company Information

Endo International plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Endo International plc
  • Ticker: ENDP
  • Exchange: NasdaqGS
  • Founded: 1920
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$950.848m
  • Shares outstanding: 226.39m
  • Website: https://www.endo.com

Number of Employees


Location

  • Endo International plc
  • Minerva House
  • First Floor
  • Dublin
  • Co. Dublin
  • 4
  • Ireland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ENDPNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJul 2000
EO7DB (Deutsche Boerse AG)YesCommon StockDEEURJul 2000
ENDP NBMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNJul 2000
0Y5FLSE (London Stock Exchange)YesCommon StockGBUSDJul 2000

Biography

Endo International plc manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. Its U.S. Branded - Specialty & Established Pharmaceuticals segment provi ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/16 23:34
End of Day Share Price2019/09/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.